MoonLake Immunotherapeutics Class A MLTX

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.

At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.

MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list. TheFly reported on June 22 that Clear Street maintained its Buy rating and $70 price target on MLTX. The firm highlighted SLK’s potential in hidradenitis suppurativa following the […]

MoonLake Immunotherapeutics recently reported past Week 52 Phase 3 VELA data showing strong efficacy and a consistent safety profile for sonelokimab in moderate-to-severe hidradenitis suppurativa, including adults and adolescents, and followed this with an upsized US$200,000,000 follow-on offering of Class A shares and pre-funded warrants priced around US$20 each. An interesting angle for investors is how MoonLake is pairing positive long-term clinical outcomes with fresh capital...

The biotech firm upsized its offering to $200 million, up from the previously announced $150 million.

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinar

Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, MoonLake is expected to grant the underwriters of

Key upcoming catalysts include MoonLake's Investor Day on Monday, an FDA filing in September, and additional late-stage pipeline readouts later this year.

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trialsNamely, ~67% of patients treated with SLK achieved HiSCR75 at the one-year mark, with more than one quarter of patients achieving inflammatory remission (IH